Mellaril-S

Mellaril-S treats schizophrenia. Tell your doctor if you can not control your movements.

Mellaril-S Overview

Updated: 

Mellaril-S is a prescription medication used to treat schizophrenia. Mellaril-S belongs to a group of drugs called antipsychotics, which work by changing the activity of certain natural substances in the brain.

This medication comes in a suspension form and is typically taken three times a day. 

Common side effects of Mellaril-S include dry mouth, blurry vision, constipation, nausea, vomiting, diarrhea, and dizziness. Do not drive or operate heavy machinery until you know how Mellaril-S affects you.

This brand is no longer being manufactured. 

 

How was your experience with Mellaril-S?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Mellaril-S?

What are you taking Mellaril-S for?

Choose one
  • Other
  • Psychotic Disorders
  • Schizophrenia

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Mellaril-S work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Mellaril-S to a friend?

Generic

Back to Top

Mellaril-S Drug Class

Back to Top

Mellaril-S is part of the drug class:

Mellaril-S FDA Warning

Back to Top

Thioridazine has been shown to prolong the QTc interval in a dose related manner, and drugs with this potential, including thioridazine, have been associated with Torsades de pointes type arrhythmias and sudden death. Due to its potential for significant, possibly life threatening, proarrhythmic effects, thioridazine should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Thioridazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis.